FDA Will Revise Review Order For Generic Drugs Under GIVE Project
This article was originally published in The Pink Sheet Daily
Executive Summary
First generic products – those with no blocking patents or exclusivity protections on the reference listed drug – will get expedited review, agency says.
You may also be interested in...
Gene Logic To Share Genomic Data With FDA For Critical Path Initiative
Voluntary collaboration will help FDA develop quality standards for submission of microarray data.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.